Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 5/20 | 0.58 |
| ▸ | CES1 | P23141 | 5/20 | 0.58 |
| ▸ | FAAH | O00519 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | DGKA | P23743 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8167954 | 0.98 | FAAH (0.61) | CES2CES1FAAHALDH1A1DGKA | |
| SCHEMBL9340088 | 0.98 | FAAH (0.61) | CES2CES1FAAHALDH1A1DGKA | |
| SCHEMBL8639413 | 0.96 | CES2 (0.58) | CES2CES1FAAHALDH1A1DGKA | |
| SCHEMBL9002877 | 0.94 | FAAH (0.61) | CES2CES1FAAHDGKATSHR | |
| SCHEMBL9002350 | 0.94 | FAAH (0.61) | CES2CES1FAAHDGKATSHR | |
| SCHEMBL10882394 | 0.94 | FAAH (0.61) | CES2CES1FAAHDGKATSHR | |
| SCHEMBL910006 | 0.93 | CES1 (0.56) | CES2CES1FAAHALDH1A1DGKA | |
| SCHEMBL10881373 | 0.92 | FAAH (0.59) | CES2CES1FAAHDGKATSHR | |
| SCHEMBL10879340 | 0.92 | FAAH (0.59) | CES2CES1FAAHDGKATSHR | |
| SCHEMBL10878913 | 0.92 | FAAH (0.59) | CES2CES1FAAHDGKATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10248591-A | — | — | None | — | — | JP | disclosed |
| EP-4329743-A1 | PYRUVATE ESTERS FOR THE TREATMENT OF VIRAL DISEASES | Birkenmeier, Gerd (DE) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022228651-A1 | PYRUVATE ESTERS FOR THE TREATMENT OF VIRAL DISEASES | BIRKENMEIER GERD (DE) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022228652-A1 | MEANS AND METHOD FOR TREATING VIRAL INFECTIONS | BIRKENMEIER GERD (DE) | 2022-11-03 | — | — | WO | disclosed |
| EP-1874407-B1 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG ENTWICKLUNG UND DIAGNOSTIK GMB (DE) | 2015-09-09 | — | — | EP | disclosed |
| EP-1877141-B1 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST BACTERIA | BIOMAC PRIVATINSTITUT FUER MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG ENTWICKLUNG UND DIAGNOSTIK GM (DE) | 2013-06-12 | — | — | EP | disclosed |
| US-20100204161-A1 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use Against Bacteria | BIOMAC PRIVATINSTITUT FUR MEDIZINISHE UND ZAHMEDIZ FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| CN-1678961-B | Removing solution | DAIKIN IND LTD | 2010-05-05 | — | — | CN | disclosed |
| US-20080300303-A1 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use As Anti-Fungal Agents | BIOMAC PRIVATINSTITUT FUER MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
| EP-1924327-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE TO COMBAT CANCER | Biomac Privatinstitut für medizinische und Zahnmedizinische Forschung, Entwicklung und Diagnostik GmbH (DE) | 2008-05-28 | — | — | EP | disclosed |
| EP-1877141-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST BACTERIA | Biomac Privatinstitut für medizinische und Zahnmedizinische Forschung, Entwicklung und Diagnostik GmbH (DE) | 2008-01-16 | — | — | EP | disclosed |
| EP-1874407-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS | Biomac Privatinstitut für medizinische und Zahnmedizinische Forschung, Entwicklung und Diagnostik GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108679-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE TO COMBAT CANCER | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108680-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST PROTOZOA AND HELMINTHES | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108682-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108681-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST BACTERIA | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| JP-H10248591-A | PRODUCTION OF OPTICALLY ACTIVE ALCOHOL | SUMITOMO CHEM CO LTD | 1998-09-22 | — | — | JP | disclosed |
| US-4365086-A | CURING AGENTS FOR THERMOPLASTIC ELASTOMERS | PENNWALT CORPORATION (US) | 1982-12-21 | — | — | US | disclosed |
| US-4328360-A | VULCANIZING AGENT FOR THERMOPLASTIC RESINS | PENNWALT CORPORATION (US) | 1982-05-04 | — | — | US | disclosed |
| US-4052543-A | VULCANIZABLE AND VULCANIZED COMPOSITIONS CONTAINING POLYPEROXIDE | PENNWALT CORPORATION (US) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300303-A1 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use As Anti-Fungal Agents | GLO1, G6PD, GRHPR | CES2 1309/4885CES1 338/4885FAAH 3459/4885 |
| US-20100204161-A1 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use Against Bacteria | GLO1, G6PD, GRHPR | CES2 780/4885CES1 236/4885FAAH 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.